Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21779383 | 1.00 | HRH3 (0.51) | HRH3CARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL10057689 | 0.91 | HRH3 (0.57) | HRH3CARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL11221320 | 0.87 | CTSL (0.57) | HRH3CARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL20147986 | 0.82 | CARM1 (0.55) | HRH3CARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL21652009 | 0.81 | CARM1 (0.53) | HRH3CARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL15800371 | 0.80 | CARM1 (0.58) | HRH3CARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL18596737 | 0.80 | CARM1 (0.58) | HRH3CARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL18596866 | 0.80 | CARM1 (0.58) | HRH3CARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL24213030 | 0.77 | CARM1 (0.59) | HRH3CARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL22098608 | 0.76 | HRH3 (0.58) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023222850-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023067355-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022010537-A1 | GAS41 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | GAS6, HIF1AN, TMEM41B | HRH3 3775/4885CARM1 634/4885PRMT6 91/4885 |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | HRH3 1157/4885CARM1 1444/4885PRMT6 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.